Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | lipase containing protein, putative | 0.0405 | 0.7075 | 0.5 |
Echinococcus multilocularis | sn1 specific diacylglycerol lipase beta | 0.0405 | 0.7075 | 0.7075 |
Trypanosoma brucei | lipase domain protein, putative | 0.0405 | 0.7075 | 0.5 |
Loa Loa (eye worm) | lipase | 0.0405 | 0.7075 | 0.7075 |
Trypanosoma brucei | lipase domain protein, putative | 0.0405 | 0.7075 | 0.5 |
Onchocerca volvulus | 0.0405 | 0.7075 | 1 | |
Trichomonas vaginalis | lipase containing protein, putative | 0.0405 | 0.7075 | 0.5 |
Schistosoma mansoni | amidase | 0.0545 | 1 | 1 |
Schistosoma mansoni | fatty-acid amide hydrolase | 0.0545 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0405 | 0.7075 | 0.5 |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.0132 | 0.1344 | 0.5 |
Echinococcus granulosus | sn1 specific diacylglycerol lipase beta | 0.0405 | 0.7075 | 0.7075 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0132 | 0.1344 | 0.5 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0545 | 1 | 1 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0545 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0405 | 0.7075 | 0.5 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0545 | 1 | 1 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0545 | 1 | 1 |
Brugia malayi | Lipase family protein | 0.0405 | 0.7075 | 0.7075 |
Loa Loa (eye worm) | hypothetical protein | 0.0545 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0405 | 0.7075 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | > 20 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce CMV(AD-169) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 20 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce CMV(Davis) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 20 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce CMV(AD-169) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 20 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce CMV(Davis) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 50 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce VZV TK+(YS) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 50 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce VZV TK+(OKA) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 50 mg ml-1 | Minimum inhibitory concentration required to reduce VZV TK-(07-1) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 50 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce VZV TK-(YS/R) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 50 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce VZV TK+(YS) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 50 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce VZV TK+(OKA) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 50 mg ml-1 | Minimum inhibitory concentration required to reduce VZV TK-(07-1) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 50 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce VZV TK-(YS/R) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 100 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-1(IIIb) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 100 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-2(ROD) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 100 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-1(IIIb) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 100 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-2(ROD) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | = 152 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce MSV induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | = 152 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce MSV induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | = 300 mg ml-1 | Compound was tested in vitro for minimum inhibitory concentration required to reduce HSV-1(KOS) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | = 300 mg ml-1 | Compound was tested in vitro for minimum inhibitory concentration required to reduce HSV-1(KOS) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 400 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-1 TK-(B2006) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 400 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce VV induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 400 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-1 TK-(B2006) induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
MIC (functional) | > 400 mg ml-1 | Compound was tested in vitro for Minimum inhibitory concentration required to reduce VV induced cytopathicity in Human MT-4 cells | ChEMBL. | 8765509 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.